

## Supplementary Material

### Cost and cost-effectiveness of Hepatitis C virus self-testing in four settings: an economic evaluation

Josephine G. Walker PhD <sup>1</sup>, Elena Ivanova PhD<sup>3</sup>, Muhammad S. Jamil PhD<sup>2</sup>, Associate Prof Jason J. Ong PhD <sup>4</sup>, Prof Philippa Easterbrook MD<sup>2</sup>, Emmanuel Fajardo <sup>2,3</sup>, Cheryl Case Johnson MA<sup>2</sup>, Niklas Luhmann MScPH<sup>2</sup>, Prof Fern Terris-Prestholt PhD<sup>5</sup>, Prof Peter Vickerman DPhil<sup>1</sup>, Sonjelle Shilton MPH<sup>3</sup>

1. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
2. Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland
3. FIND, Geneva, Switzerland
4. London School of Hygiene & Tropical Medicine, London, UK
5. Joint UN programme on HIV and AIDS, Geneva, Switzerland

#### Table of Contents

<b><i>Case study assumptions and current testing guidelines in each setting.....</i></b>	<b>2</b>
<b><i>Supplementary Figures.....</i></b>	<b>3</b>
Supplementary Figure 1.....	3
Supplementary Figure 2.....	4
Supplementary Figure 3.....	5
<b><i>Supplementary Tables.....</i></b>	<b>6</b>
Supplementary Table 1.....	6
Supplementary Table 2.....	7
Supplementary Table 3.....	8
<b><i>References .....</i></b>	<b>9</b>

## Case study assumptions and current testing guidelines in each setting

The current guidelines for testing and treatment for HCV vary in each of the four country settings.

In Georgia, an ongoing HCV elimination program that began in 2015 involves a large scale up in access to testing and treatment at very low cost to the patient[1]. A sero-survey conducted in 2021 indicates that middle aged men still hold a high burden of infections and have been accessing treatment at a lower rate than other groups (data pending publication). The standard of care is that HCV testing is widely available, including mandatory testing for all inpatients. We assume that self-testing will be implemented on a postal model, with self-tests distributed through the post following outreach to the target population of men aged 40-49. This would not be integrated within any existing HIV self-testing program.

In Kenya, we focus on PWID, where the standard of care is to have drop-in harm reduction centers which offer facility-based HCV testing[2]. National guidelines recommend regular testing of PWID and other high risk groups[3]. The self-testing approach would be peer-led testing, whereby outreach workers from the harm reduction centers go into the community with self-tests and provide a demonstration and guidance on test use. We assume this would also be integrated within existing HIV self-testing programs, as costs are based on adding HCVST to HIVST in other east African settings[4].


In Vietnam we also assume that PWID would be tested through a peer-led testing approach. Ongoing research uses respondent-driven sampling surveys to recruit PWID to testing and treatment interventions[5]. Like in Kenya, we assume that outreach workers from community-based organisations that provide harm reduction services would provide the target population with demonstration and guidance on self-test usage. However, we assume this would be separate from any HIV self-testing programs.

In China, where the target population is MSM, we assume that existing testing is available privately or through community-based organisations. The model of care for self-testing would be advertising through social media and posting tests when requested. An existing study of HIV self-testing used this model and the cost of the test was reimbursed to the patient if the test result was uploaded, we assume the HCVST program would build on this model[6].

## Supplementary Figures


### Supplementary Figure 1

The number of people diagnosed in each setting for each modelled scenario considered in the sensitivity analysis, compared to the counterfactual with no HCVST (in green), and the base case with HCVST (in red). Bars outlined in black indicate the scenarios with and without HCVST in which EIA is the standard of care antibody test.




Supplementary Figure 2

The cost of implementing HCVST per diagnosed patient (excluding the costs of treatment) in each population, for each modelled sensitivity analysis, compared to the counterfactual with no HCVST (in green), and the base case (in red). Bars outlined in black indicate the scenarios with and without HCVST in which EIA is the standard of care antibody test.



Supplementary Figure 3

*Tornado plot showing the impact of varying parameters in sensitivity analysis on the incremental cost per cure. Note that the x-axis scale is different for each country.*



\*The vertical line represents the base case incremental cost per cure as shown in Table 6, and the end of each bar represents the incremental cost per cure in each modelled scenario, with the length of the bar representing the magnitude of the difference from the base case.

## Supplementary Tables

Supplementary Table 1

*Transition and cost parameters used in model represented in Figure 1. At each step, the transition parameters leaving a particular cell sum to 1.*

<b>Step</b>	<b>Transition to step</b>	<b>Cost at step</b>
Initial population	Total population of interest * proportion with unknown status	-
<b>Of initial population:</b>		
Proportion receiving facility-based serologic testing	Standard testing rate minus proportion that use self-test instead	Test cost
Proportion receiving self-testing	New tests plus proportion that switch to using self-test instead of standard test	Self test cost + distribution
Proportion not tested	1 – standard testing and self-testing	-
<b>Of those with facility-based serologic testing:</b>		
Anti-HCV positive by facility-based (FB) test	Prevalence * (FB sensitivity) + (1-prevalence)*(1- FB specificity)	-
Anti-HCV negative by facility-based (FB) test	1 – [Prevalence * (FB sensitivity) + (1-prevalence)*(1-FB specificity)]	-
<b>Of those using self-testing:</b>		
HCVAb positive by self-test (ST) accessing facility (direct to NAT or standard care pathway)	(prevalence*ST sensitivity*inter-reader agreement + (1-prevalence)*(1-ST specificity*inter-reader agreement)) * (1 - % test failure)* % link to care if positive	-
HCVAb negative by self-test (ST) accessing facility	(1 – (prevalence*ST sensitivity*inter-reader agreement + (1-prevalence)*(1-ST specificity*inter-reader agreement)) * (1 - % test failure) * % link to care if negative	-
Unclear result or self-test failure (invalid)	% test failure * % link to care if invalid	-
Self-test result not reported	1 – total above three rows	-
<b>Of those reporting self-test results (repeat serologic testing scenario):</b>		
Retest antibody after invalid HCVAb self-test	% re-tested if link to care	Test cost
Retest antibody (repeat serologic testing scenario) after positive HCVAb self-test	% re-tested if link to care	Test cost
Don't retest antibody after self test	1 – % re-tested antibody	-
<b>Of those receiving facility-based serologic testing after positive self-test:</b>		
HCVAb positive by facility-based (FB) test after positive self-test (ST)	[(Prevalence * ST sensitivity*inter-reader agreement) * FB sensitivity + (1 - Prevalence)* (1-ST specificity*inter-reader agreement) * (1-FB specificity)] / [Prevalence * (ST sensitivity*inter-reader agreement) + (1-prevalence)*(1-ST specificity*inter-reader agreement)]	-
HCVAb negative by facility-based after positive self test	1 – positive by facility-based test	-
<b>Of those receiving facility-based serologic testing after invalid self-test:</b>		
HCVAb positive by facility-based serologic test after invalid self test	Prevalence * (FB sensitivity) + (1-prevalence)*(1- FB specificity)	-
HCVAb negative by facility-based serologic after invalid self test	1 - Prevalence * (FB sensitivity) + (1-prevalence)*(1-FB specificity)	-

Supplementary Table 2

*Transitions and costs from confirmation of viraemic infection onwards (shown in Figure 2).*

Step	Transition to step	Cost at step
<b>Of those anti-HCV positive eligible for NAT testing:</b>		
Confirm infection by NAT after facility-based test	% Receive NAT test	NAT cost
Confirm infection by NAT directly after self-test	% re-tested if linked to care	NAT cost
No confirmatory test	1 – receive NAT	-
<b>Of those receiving NAT testing:</b>		
Viraemic infection from self-test direct to NAT	$\frac{\text{Viraemic proportion of Ab positive} * (\text{Prevalence} * (\text{ST sensitivity} * \text{inter-reader agreement}) / (\text{Prevalence} * (\text{ST sensitivity} * \text{inter-reader agreement}) + (1 - \text{prevalence}) * (1 - \text{ST specificity} * \text{inter-reader agreement}))}{1}$	-
Viraemic infection by NAT after facility-based test following self-test	$\frac{\text{Viraemic proportion of Ab positive} * (\text{Prevalence} * \text{ST sensitivity} * \text{inter-reader agreement}) * \text{FB sensitivity} / (\text{Prevalence} * \text{ST sensitivity} * \text{inter-reader agreement}) * \text{FB sensitivity} + (1 - \text{Prevalence}) * (1 - \text{ST specificity} * \text{inter-reader agreement}) * (1 - \text{FB specificity})}{1}$	-
Viraemic infection by NAT after facility-based test only	$\frac{\text{Viraemic proportion of Ab positive} * (\text{Prevalence} * (\text{FB sensitivity}) / (\text{Prevalence} * (\text{FB sensitivity}) + (1 - \text{prevalence}) * (1 - \text{FB specificity}))}{1}$	-
Not currently viraemic	1 – positive NAT test	
<b>Of those with chronic infection:</b>		
Link to care for pre-treatment assessment	Link to care (observed care cascade)	Pre-treatment costs
Not linked to care	1 – link to care	-
<b>Of those linked to care:</b>		
Start treatment	Treated (observed care cascade)	Treat cost
Not treated	1 - treated	-
<b>Of those treated:</b>		
SVR12 achieved	% Tested for SVR * % cure	NAT cost
SVR12 not achieved	% Tested for SVR * (1- % cure)	NAT cost
SVR12 not assessed	Not tested for SVR	-

Supplementary Table 3

*Parameter values that are the same across all four settings*

<b>Parameter</b>	<b>Value</b>	<b>Source</b>
Percent of facility-based tests that are replaced by self-tests	10%	Assumption
Blood-based RDT sensitivity	95%	[7]
Blood-based RDT specificity	100%	[7]
Oral-fluid based RDT sensitivity	98%	[8]
Oral-fluid based RDT specificity	100%	[8]
Test failure rate (invalid result)	3%	Assumption
Link to facility with positive self-test	65%	[9]
Link to facility with negative self-test	5%	Assumption
Link to facility with invalid self-test	65%	[9]
Receive facility-based test if link to facility with positive or invalid self-test	100%	Assumption
Receive follow up test in clinic if report negative self-test result	0%	Assumption
Self-test unit cost (oral-fluid based)	5.63 USD	Assumption
Self-test unit cost (blood-based)	2.25 USD	Assumption



## References

1. Averhoff, F., et al., *Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia*. J Hepatol, 2020. **72**(4): p. 680-687.
2. Mafirakureva, N., et al., *An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis*. Addiction, 2022. **117**(2): p. 411-424.
3. Gastroenterology Society of Kenya, *Guidelines for the treatment of chronic hepatitis B & C viral infections in Kenya*. 2014, Gastroenterology Society of Kenya: Nairobi.
4. Manganah, C., et al., *Economic cost analysis of door-to-door community-based distribution of HIV self-test kits in Malawi, Zambia and Zimbabwe*. J Int AIDS Soc, 2019. **22 Suppl 1**: p. e25255.
5. Rapoud, D., et al., *Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C)*. BMJ Open, 2020. **10**(11): p. e039234.
6. Ong, J., et al., *Cost-effectiveness of community-based organization led HIV self-testing vs. facility-based HIV rapid-diagnostic testing among men who have sex with men in China*. Unpublished.
7. Vetter, B.N., et al., *Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study*. J Infect Dis, 2020.
8. Tang, W., et al., *Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature*. BMC Infect Dis, 2017. **17**(Suppl 1): p. 695.
9. Jamil, M., et al., *ANNEX 3: Should HIV self-testing be offered as an additional approach to delivering HIV testing services? A GRADE systematic review and values and preferences*. 2019, World Health Organization: Geneva.